Sobetirome as a novel therapeutic agent in fibrotic lung diseases

• Idiopathic pulmonary fibrosis (IPF) is a lethal progressive chronic lung disease of unknown origin, with median survival of 3 years. 6M worldwide and 190,000 in USA are affected with IPF.
• Market expected to reach $3.2 billion by 2025.
• 2 FDA approved drugs show 40% reduction in disease progression, but no impact on QOL or survival. Side effects are significant (gastrointestinal, liver and photosensitivity), leading to poor patient compliance.
• Sobetirome (GC-1) is well characterized thyromimetic drug. in vivo animal proof of concept in IPF shows significant resolution of fibrosis
• IP Status: PCT/US 15/317,276
• Innovator: Naftali Kaminski, M.D.